<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CROMOLYN SODIUM- cromolyn sodium solution, concentrate </strong><br>Prasco Laboratories<br></p></div>
<h1>Cromolyn Sodium, USP<br>Oral Concentrate</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_510c52e6-bba5-42b7-8bb1-306db1846de2"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx Only</p>
<p>Iss. 10/10</p>
<p>CROMp-10-01</p>
<p><span class="Bold">For Oral Use Only – Not for Inhalation or Injection.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_d559f345-1bd2-44df-bcff-a01db072c9c8"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Each 5 mL ampule of Cromolyn Sodium, USP contains 100 mg cromolyn sodium, USP, in purified water. Cromolyn sodium is a hygroscopic, white powder having little odor. It may leave a slightly bitter aftertaste. Cromolyn Sodium, USP Oral Concentrate is clear, colorless, and sterile. It is intended for oral use.</p>
<p>Chemically, cromolyn sodium is disodium 5,5’-[(2-hydroxytrimethylene)dioxy]bis[4-oxo-4<span class="Italics">H</span>-1-benzopyran-2-carboxylate]. The empirical formula is C<span class="Sub">23</span>H<span class="Sub">14</span>Na<span class="Sub">2</span>O<span class="Sub">11</span>; the molecular weight is 512.34. Its chemical structure is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-1.jpg"></div>
<p>Pharmacologic Category: Mast cell stabilizer</p>
<p>Therapeutic Category: Antiallergic</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_3bf0421e-d932-43e3-9223-832e4b50d137"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> animal studies have shown that cromolyn sodium inhibits the release of mediators from sensitized mast cells. Cromolyn sodium acts by inhibiting the release of histamine and leukotrienes (SRS-A) from the mast cell.</p>
<p>Cromolyn sodium has no intrinsic vasoconstrictor, antihistamine, or glucocorticoid activity.</p>
<p>Cromolyn sodium is poorly absorbed from the gastrointestinal tract. No more than 1% of an administered dose is absorbed by humans after oral administration, the remainder being excreted in the feces. Very little absorption of cromolyn sodium was seen after oral administration of 500 mg by mouth to each of 12 volunteers. From 0.28 to 0.50% of the administered dose was recovered in the first 24 hours of urinary excretion in 3 subjects. The mean urinary excretion of an administered dose over 24 hours in the remaining 9 subjects was 0.45%.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_895f353e-8ff8-4ffb-a3b6-80cb95e635ca"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES:</h1>
<p class="First"> Four randomized, controlled clinical trials were conducted with Cromolyn Sodium, USP in patients with either cutaneous or <span class="product-label-link" type="condition" conceptid="4246284" conceptname="Systemic mast cell disease">systemic mastocytosis</span>; two of which utilized a placebo-controlled crossover design, one utilized an active-controlled (chlorpheniramine plus cimetidine) crossover design, and one utilized a placebo-controlled parallel group design. Due to the rare nature of this disease, only 36 patients qualified for study entry, of whom 32 were considered evaluable. Consequently, formal statistical analyses were not performed. Clinically significant improvement in <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>) were seen in the majority of patients with some improvement also seen for cutaneous manifestations (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>) and cognitive function. The benefit seen with Cromolyn Sodium, USP 200 mg QID was similar to chlorpheniramine (4 mg QID) plus cimetidine (300 mg QID) for both cutaneous and systemic symptoms of mastocytosis. </p>
<p> Clinical improvement occurred within 2-6 weeks of treatment initiation and persisted for 2-3 weeks after treatment withdrawal. Cromolyn Sodium, USP did not affect urinary histamine levels or peripheral <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, although neither of these variables appeared to correlate with disease severity. Positive clinical benefits were also reported for 37 of 51 patients who received Cromolyn Sodium, USP in United States and foreign humanitarian programs. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_690cd3c7-3f10-4ce4-8a13-61f7d9f1d3e4"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Cromolyn Sodium, USP is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> in some patients.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_6dd51e61-1660-4146-8875-d1394be1f045"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Cromolyn Sodium, USP is contraindicated in those patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to cromolyn sodium.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_c3b8cc22-8299-48cf-bc42-6e565f89a1b6"></a><a name="section-7"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First"><span class="Bold">The recommended dosage should be decreased in patients with decreased renal or hepatic function. Severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> may occur rarely in association with cromolyn sodium administration.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_2f054780-1707-40c8-aabe-5b3103b602e7"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">In view of the biliary and renal routes of excretion of Cromolyn Sodium, USP, consideration should be given to decreasing the dosage of the drug in patients with impaired renal or hepatic function.</p>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_40906786-51bb-4382-b7ba-188d39082291"></a><a name="section-8.1"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility:</h2>
<p class="First">In carcinogenicity studies in mice, hamsters, and rats, cromolyn sodium had no neoplastic effects at intraperitoneal doses up to 150 mg/kg three days per week for 12 months in mice, at intraperitoneal doses up to 53 mg/kg three days per week for 15 weeks followed by 17.5 mg/kg three days per week for 37 weeks in hamsters, and at subcutaneous doses up to 75 mg/kg six days per week for 18 months in rats. These doses in mice, hamsters, and rats are less than the maximum recommended daily oral dose in adults and children on a mg/m<span class="Sup">2</span> basis.</p>
<p>Cromolyn sodium showed no mutagenic potential in Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/microsome plate assays, mitotic gene conversion in <span class="Italics">Saccharomyces cerevisiae</span> and in an <span class="Italics">in vitro</span> cytogenetic study in human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. </p>
<p>In rats, cromolyn sodium showed no evidence of impaired fertility at subcutaneous doses up to 175 mg/kg in males (approximately equal to the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis) and 100 mg/kg in females (less than the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis). </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_3425442b-978b-43fb-a73f-9ee9fc661b38"></a><a name="section-8.2"></a><p></p>
<h2>Pregnancy:  Pregnancy Category B.</h2>
<p class="First">In reproductive studies in pregnant mice, rats, and rabbits, cromolyn sodium produced no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> at subcutaneous doses up to 540 mg/kg in mice (approximately equal to the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis) and 164 mg/kg in rats (less than the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis) or at intravenous doses up to 485 mg/kg in rabbits (approximately 4 times the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis). There are, however, no adequate and well controlled studies in pregnant women. </p>
<p>Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b7c4dc7e-99de-4fef-9c02-faf747b5f123"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interaction During Pregnancy:</h2>
<p class="First">In pregnant mice, cromolyn sodium alone did not cause significant increases in resorptions or major malformations at subcutaneous doses up to 540 mg/kg (approximately equal to the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis). Isoproterenol alone increased both resorptions and major malformations (primarily <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>) at a subcutaneous dose of 2.7 mg/kg (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m<span class="Sup">2</span> basis). The incidence of major malformations increased further when cromolyn sodium at a subcutaneous dose of 540 mg/kg was added to isoproterenol at a subcutaneous dose of 2.7 mg/kg. No such interaction was observed in rats or rabbits.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_17d5d810-24b1-403e-b3d9-c9d26ce62953"></a><a name="section-8.4"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cromolyn Sodium, USP is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_d059347a-f64a-4f5d-9647-3b8b625081d3"></a><a name="section-8.5"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">In adult rats no adverse effects of cromolyn sodium were observed at oral doses up to 6144 mg/kg (approximately 25 times the maximum recommended daily oral dose in adults on a mg/m<span class="Sup">2</span> basis). In neonatal rats, cromolyn sodium increased mortality at oral doses of 1000 mg/kg or greater (approximately 9 times the maximum recommended daily oral dose in infants on a mg/m<span class="Sup">2</span> basis) but not at doses of 300 mg/kg or less (approximately 3 times the maximum recommended daily oral dose in infants on a mg/m<span class="Sup">2</span> basis). Plasma and kidney concentrations of cromolyn after oral administration to neonatal rats were up to 20 times greater than those in older rats. In term infants up to six months of age, available clinical data suggest that the dose should not exceed 20 mg/kg/day. The use of this product in pediatric patients less than two years of age should be reserved for patients with severe disease in which the potential benefits clearly outweigh the risks.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_16c2a7b3-9787-41ae-96e0-bd7482ed0529"></a><a name="section-8.6"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of Cromolyn Sodium, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_b2cc3b1a-06ee-440a-8803-6f07376de7b4"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Most of the adverse events reported in mastocytosis patients have been transient and could represent symptoms of the disease. The most frequently reported adverse events in mastocytosis patients who have received Cromolyn Sodium, USP during clinical studies were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, each of which occurred in 4 of the 87 patients. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> were each reported in 3 patients and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> in 2 patients each. One report of <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> was also recorded.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_525edfca-82fa-4e2d-9601-4ea936f41f19"></a><a name="section-9.1"></a><p></p>
<h2>Other Adverse Events:</h2>
<p class="First">Additional adverse events have been reported during studies in other clinical conditions and from worldwide postmarketing experience. In most cases the available information is incomplete and attribution to the drug cannot be determined. The majority of these reports involve the gastrointestinal system and include: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="134681" conceptname="Diffuse spasm of esophagus">esophagospasm</span>.</p>
<p>Other less commonly reported events (the majority representing only a single report) include the following: </p>
<ul class="Disk">
<li>Skin: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>/<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>/ burning, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span></li>
<li>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of legs</li>
<li>Neurologic: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></li>
<li>Psychiatric: <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, behavior change, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></li>
<li>Heart Rate: <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span> (PVCs), <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></li>
<li>Respiratory: <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> </li>
<li>Miscellaneous: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, unpleasant taste, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, postprandial <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, hepatic function test abnormal, <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span> (LE) syndrome</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e32490ae-60bb-45a4-9daf-3e20bab984c7"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">NOT FOR INHALATION OR INJECTION. SEE DIRECTIONS FOR USE.</p>
<p>The usual starting dose is as follows:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_36685eca-618d-47dc-8d05-86335d8f5987"></a><a name="section-10.1"></a><p></p>
<h2>Adults and Adolescents (13 Years and Older):</h2>
<p class="First">Two ampules four times daily, taken one-half hour before meals and at bedtime.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b8f2c5ed-8b9b-45c0-a564-3d27cf1d9d3a"></a><a name="section-10.2"></a><p></p>
<h2>Children 2-12 Years:</h2>
<p class="First">One ampule four times daily, taken one-half hour before meals and at bedtime.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a52bbcd5-f130-4e10-b4d4-d72fdcf62503"></a><a name="section-10.3"></a><p></p>
<h2>Pediatric Patients Under 2 Years:</h2>
<p class="First">Not recommended.</p>
<p>If satisfactory control of symptoms is not achieved within two to three weeks, the dosage may be increased but should not exceed 40 mg/kg/day.</p>
<p>Patients should be advised that the effect of Cromolyn Sodium, USP therapy is dependent upon its administration at regular intervals, as directed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_62514319-dd3f-454f-a1ac-55a1add0cd99"></a><a name="section-10.4"></a><p></p>
<h2>Maintenance Dose:</h2>
<p class="First">Once a therapeutic response has been achieved, the dose may be reduced to the minimum required to maintain the patient with a lower degree of symptomatology. To prevent relapses, the dosage should be maintained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a17636fc-8f9f-4d9a-9545-53a807bbc850"></a><a name="section-10.5"></a><p></p>
<h2>Administration:</h2>
<p class="First">Cromolyn Sodium, USP should be administered as a solution at least 1/2 hour before meals and at bedtime after preparation according to the following directions:</p>
<p>    1. Break open ampule(s) and squeeze liquid contents of ampule(s) into a glass of water.<br>    2. Stir solution.<br>    3. Drink all of the liquid.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_434dd02b-2bbc-498b-8a10-8b8240943c3e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Cromolyn Sodium, USP Oral Concentrate is an unpreserved, colorless solution supplied in a low density polyethylene plastic unit dose ampule with 8 ampules per foil pouch. Each 5 mL ampule contains 100 mg cromolyn sodium, USP, in purified water.</p>
<p>       NDC 66993-470-96     96 ampules x 5 mL</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_625d1ac2-0275-4861-b1a9-c777e80db7b2"></a><a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First">Cromolyn Sodium, USP Oral Concentrate should be stored between 15°-30°C (59°-86°F) and protected from light. Do not use if it contains a precipitate or becomes discolored. Keep out of the reach of children.</p>
<p>Store ampules in foil pouch until ready for use.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_69367723-d4dc-46bd-9e6c-82bdfa13f024"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Distributed by:</p>
<p><span class="Bold">Prasco Laboratories</span><br>Mason, OH 45040 USA</p>
<p>Manufactured by: <br>Catalent Pharma Solutions<br>Woodstock, IL 60098 USA</p>
<p>Iss. 10/10</p>
<p>CROMp-10-01</p>
<p><span class="Bold">PHARMACIST – DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_93c9145b-1e8b-41d0-b0d8-f6af0756cf16"></a><a name="section-13"></a><p></p>
<h1>PATIENT INSTRUCTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d72d7ed2-587e-4cc5-b39b-3e0d476cddfc"></a><a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Cromolyn Sodium, USP </span></p>
<p><span class="Bold">Oral Concentrate</span></p>
<p><span class="Bold">For Oral Use Only – Not for Inhalation or Injection.</span></p>
<p><span class="Bold">How to Use Cromolyn Sodium, USP:</span></p>
<p>As with all prescription drugs, follow the directions for dosage that your physician recommends.</p>
<p>The effect of Cromolyn Sodium, USP therapy is dependent upon its administration at REGULAR intervals, for as long as recommended by your physician.</p>
<p><span class="Bold">Usual Starting Dose:</span><br><span class="Bold">Adults and Adolescents (13 Years and Older):</span><br>Two ampules four times daily, taken one-half hour before meals and at bedtime.</p>
<p><span class="Bold">Children 2-12 Years:</span><br>One ampule four times daily, taken one-half hour before meals and at bedtime.</p>
<p><span class="Bold">Note:</span></p>
<p>Your physician may decide to increase OR decrease your dosage to achieve optimum results with Cromolyn Sodium, USP. However, do not change your dose or stop taking Cromolyn Sodium, USP without first consulting your physician.</p>
<p><span class="Bold">Care &amp; Storage:</span></p>
<p>Cromolyn Sodium, USP Oral Concentrate should be stored between 15°-30°C (59°-86°F) and protected from light. Do not use if it contains a precipitate (particles or cloudiness) or becomes discolored. Keep out of the reach of children. </p>
<p>Store ampules in foil pouch until ready for use.</p>
<p>Recycling Information: Cromolyn Sodium, USP Oral Concentrate ampules are made with a low density polyethylene plastic (recycling material code:<img alt="recycling material code" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-2.jpg"> LDPE).</p>
<p><span class="Bold">Directions for Use:</span></p>
<p>    1. Open foil pouch by tearing at serrated edge as shown.<br><img alt="Directions for Use: Step 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-3.jpg"></p>
<p>    2. Remove ampule(s) from the strip.<br><img alt="Directions for Use: Step 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-4.jpg"></p>
<p>    3. Open the ampule by twisting off the tabbed top section.<br><img alt="Directions for Use: Step 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-5.jpg"></p>
<p>    4. Squeeze liquid contents into a glass of water. Stir solution. Drink all of the liquid. Discard the empty ampule.<br><img alt="Directions for Use: Step 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-6.jpg"></p>
<p>Distributed by:</p>
<p><span class="Bold">Prasco Laboratories<br></span>Mason, OH 45040 USA</p>
<p>Manufactured by: <br>Catalent Pharma Solutions<br>Woodstock, IL 60098 USA</p>
<p>Iss. 10/10</p>
<p>CROMp-10-01</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_7b8ea44d-ba34-49ea-8a18-be195f162aad"></a><a name="section-14"></a><p></p>
<h1>PRINICIPAL DISPLAY PANEL - Carton Side and Front  Panel</h1>
<div class="Figure">
<img alt="Carton Side and Front Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-7.jpg"><p class="MultiMediaCaption">Carton Side and Front Panel</p>
</div>
<p class="First">NDC 66993-470-96</p>
<p>PRASCO</p>
<p><span class="Bold">Cromolyn Sodium, USP</span></p>
<p>Oral Concentrate</p>
<p><span class="Bold">FOR ORAL USE ONLY - </span></p>
<p><span class="Bold">NOT FOR INHALATION OR INJECTION.</span></p>
<p>100 mg/5 mL</p>
<p>96 Plastic Ampules</p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_64138d91-6fb6-4829-ab90-823e72b8e084"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Carton Side, Back and Top Panel</h1>
<div class="Figure">
<img alt="Carton Side, Back and Top Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=169a439e-aa20-4cdf-bbe0-6b17934e8355&amp;name=cromolyn-sodium-usp-8.jpg"><p class="MultiMediaCaption">Carton Side, Back and Top Panel</p>
</div>
<p class="First">NDC 66993-470-96</p>
<p>PRASCO</p>
<p><span class="Bold">Cromolyn Sodium, USP</span></p>
<p>Oral Concentrate</p>
<p>Distributed by:</p>
<p><span class="Bold">Prasco Laboratories</span>, Mason, OH 45040 USA</p>
<p>Manufactured by: <br>Catalent Pharma Solutions, Woodstock, IL 60098 USA</p>
<p><span class="Bold">DESCRIPTION:</span>  Each 5 mL ampule contains 100 mg cromolyn sodium, USP, in purified water.</p>
<p><span class="Bold">NOTE:</span>  See package circular for full prescribing information including contraindications, warnings, and precautions.</p>
<p>Cromolyn Sodium, USP Oral Concentrate should be stored between 15°-30°C (59°-86°F) and protected from light.  Do not use if it contains a precipitate or becomes discolored. Keep out of the reach of children.</p>
<p>Store ampules in foil pouch until ready to use.</p>
<p>NDC 66993-470-96</p>
<p>PRASCO</p>
<p>Cromolyn Sodium, USP</p>
<p>Oral Concentrate</p>
<p><span class="Bold">FOR ORAL USE ONLY - </span></p>
<p><span class="Bold">NOT FOR INHALATION OR INJECTION.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>100 mg/5 mL</p>
<p>96 Plastic Ampules</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CROMOLYN SODIUM 		
					</strong><br><span class="contentTableReg">cromolyn sodium solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66993-470</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CROMOLYN SODIUM</strong> (CROMOLYN) </td>
<td class="formItem">CROMOLYN SODIUM</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66993-470-96</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">8  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA AUTHORIZED GENERIC</td>
<td class="formItem">NDA020479</td>
<td class="formItem">12/12/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Prasco Laboratories
							(065969375)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3a9d3763-8f4e-42ad-815a-a98f146f9812</div>
<div>Set id: 169a439e-aa20-4cdf-bbe0-6b17934e8355</div>
<div>Version: 4</div>
<div>Effective Time: 20111209</div>
</div>
</div> <div class="DistributorName">Prasco Laboratories</div></p>
</body></html>
